BASEL MEDICAL GROUP LTD (BMGL) Fundamental Analysis & Valuation

NASDAQ:BMGL • VGG0864B1031

Current stock price

0.62 USD
0 (0%)
At close:
0.65 USD
+0.03 (+4.84%)
After Hours:

This BMGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BMGL Profitability Analysis

1.1 Basic Checks

  • BMGL had negative earnings in the past year.
  • BMGL had a negative operating cash flow in the past year.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 -5M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -58.63%, BMGL is doing worse than 89.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -201.53%, BMGL is doing worse than 79.00% of the companies in the same industry.
  • The Return On Invested Capital of BMGL (7.76%) is better than 76.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BMGL is significantly above the industry average of 8.50%.
  • The last Return On Invested Capital (7.76%) for BMGL is well below the 3 year average (21.92%), which needs to be investigated, but indicates that BMGL had better years and this may not be a problem.
Industry RankSector Rank
ROA -58.63%
ROE -201.53%
ROIC 7.76%
ROA(3y)-10.88%
ROA(5y)N/A
ROE(3y)-45.27%
ROE(5y)N/A
ROIC(3y)21.92%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Operating Margin, with a value of 4.72%, BMGL is in line with its industry, outperforming 60.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BMGL has declined.
  • The Profit Margin and Gross Margin are not available for BMGL so they could not be analyzed.
Industry RankSector Rank
OM 4.72%
PM (TTM) N/A
GM N/A
OM growth 3Y-59.77%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 20 -20 40 -40 -60 -80

2

2. BMGL Health Analysis

2.1 Basic Checks

  • BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, BMGL has more shares outstanding
  • BMGL has a worse debt/assets ratio than last year.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • BMGL has an Altman-Z score of -0.24. This is a bad value and indicates that BMGL is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -0.24, BMGL is not doing good in the industry: 78.00% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.56 indicates that BMGL is somewhat dependend on debt financing.
  • BMGL has a Debt to Equity ratio (0.56) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -0.24
ROIC/WACC0.9
WACC8.58%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • A Current Ratio of 1.31 indicates that BMGL should not have too much problems paying its short term obligations.
  • The Current ratio of BMGL (1.31) is comparable to the rest of the industry.
  • BMGL has a Quick Ratio of 1.26. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
  • BMGL has a Quick ratio (1.26) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.26
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 5M 10M 15M

1

3. BMGL Growth Analysis

3.1 Past

  • BMGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -416.72%.
  • The Revenue has grown by 8.02% in the past year. This is quite good.
  • The Revenue has been growing slightly by 2.03% on average over the past years.
EPS 1Y (TTM)-416.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-604.19%
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2M 4M 6M 8M 10M

1

4. BMGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BMGL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • BMGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMGL is cheaper than 99.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.67
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. BMGL Dividend Analysis

5.1 Amount

  • BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BMGL Fundamentals: All Metrics, Ratios and Statistics

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (4/24/2026, 8:00:02 PM)

After market: 0.65 +0.03 (+4.84%)

0.62

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.8%
Inst Owner Change-0.17%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.65M
Revenue(TTM)16.35M
Net Income(TTM)-10.95M
AnalystsN/A
Price TargetN/A
Short Float %1.31%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.91
P/FCF N/A
P/OCF N/A
P/B 2.73
P/tB 2.73
EV/EBITDA 1.67
EPS(TTM)-0.46
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.68
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -58.63%
ROE -201.53%
ROCE 9.06%
ROIC 7.76%
ROICexc N/A
ROICexgc N/A
OM 4.72%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.88%
ROA(5y)N/A
ROE(3y)-45.27%
ROE(5y)N/A
ROIC(3y)21.92%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)33.36%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-59.77%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 1.55
Cap/Depr 47.15%
Cap/Sales 3.41%
Interest Coverage 3.79
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.26
Altman-Z -0.24
F-Score1
WACC8.58%
ROIC/WACC0.9
Cap/Depr(3y)16.59%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-416.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-604.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.8%
EBIT growth 3Y-58.95%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-261.16%
OCF growth 3YN/A
OCF growth 5YN/A

BASEL MEDICAL GROUP LTD / BMGL Fundamental Analysis FAQ

What is the fundamental rating for BMGL stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMGL.


What is the valuation status for BMGL stock?

ChartMill assigns a valuation rating of 1 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.


Can you provide the profitability details for BASEL MEDICAL GROUP LTD?

BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 2 / 10.